WATERTOWN, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...

Prurigo pigmentosa is a rare inflammatory disorder of unknown etiology. 1 However, some cases have been associated with ketosis. Herein, we report a case of prurigo pigmentosa triggered by a ketogenic ...

IN a significant advancement for the management of prurigo nodularis, a chronic and debilitating skin condition, a new systematic review highlights the promise of emerging biologic and targeted ...

Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including vitiligo, atopic dermatitis (AD), prurigo ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...